



# CONTENTS

	<i>Pages</i>
<b>DEFINITIONS</b> .....	1
<b>LETTER FROM THE BOARD</b> .....	3
1. <b>Letter from the Board of Directors</b> .....	4
2. <b>Letter from the Board of Directors</b> .....	4
2022 <b>Letter from the Board of Directors</b> .....	4
2022 <b>Letter from the Board of Directors</b> .....	5
2022 <b>Letter from the Board of Directors</b> .....	5
2022 <b>Letter from the Board of Directors</b> .....	5
2022 <b>Letter from the Board of Directors</b> .....	5
2022 <b>Letter from the Board of Directors</b> .....	5
2022 <b>Letter from the Board of Directors</b> .....	6
2022 <b>Letter from the Board of Directors</b> .....	6
2022 <b>Letter from the Board of Directors</b> .....	7
2022 <b>Letter from the Board of Directors</b> .....	7
2022 <b>Letter from the Board of Directors</b> .....	9
2022 <b>Letter from the Board of Directors</b> .....	9
2022 <b>Letter from the Board of Directors</b> .....	9
3. <b>Letter from the Board of Directors</b> .....	9
4. <b>Letter from the Board of Directors</b> .....	10
5. <b>Letter from the Board of Directors</b> .....	11
<b>APPENDIX I – PROFILES OF THE PROPOSED SIXTH SESSION OF THE BOARD</b> ...	12
<b>APPENDIX II – AMENDMENT OF ARTICLES OF ASSOCIATION</b> .....	18
<b>NOTICE OF THE 2022 ANNUAL GENERAL MEETING</b> .....	20

*Notice of the 2022 Annual General Meeting of the Board of Directors of the Company*

---

## DEFINITIONS

---

*I say a hypothesis is necessary if, if it is true, it is necessary that it is true.*

A

---

## DEFINITIONS

---

... (深圳市樂仁科技有限公司),

$$I_{\mathbb{R}^n}^{\alpha} f(x) = \int_{\mathbb{R}^n} \frac{f(y)}{|x-y|^{n-\alpha}} dy, \quad x \in \mathbb{R}^n, \quad (1.1)$$

... ..

[illegible]

**Figure 1**

1.00 A ( ) ( )

$$\frac{1}{2} \leq \frac{1}{2} \leq \frac{1}{2} \quad (1) \quad \frac{1}{2} \leq \frac{1}{2} \leq \frac{1}{2} \quad (2) \quad \frac{1}{2} \leq \frac{1}{2} \leq \frac{1}{2} \quad (3)$$

29, 2004,

*Journal of Management Education* 36(7) 809-824

)(烏魯木齊水滴石穿股權投資合夥企業(有限合夥)),

[illegible][illegible]

•  $\lim_{x \rightarrow 0} \frac{1}{x} = \infty$  (.)      (.)      •  $\lim_{x \rightarrow 0} \frac{1}{x^2} = \infty$  (.)       $\lim_{x \rightarrow 0} \frac{1}{x^3} = \infty$  (.)

• 1. ( ) 2. ( ) 3. ( ) 4. ( ) 5. ( ) 6. ( ) 7. ( ) 8. ( ) 9. ( ) 10. ( )

(深圳市多普樂實業

發展有限公司), 本公司與該公司訂立獨家代理協議, 該協議將於2018年12月31日屆滿。該協議的詳情載於附錄五。

---

## LETTER FROM THE BOARD

---



**SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.**

**( 深圳市海普瑞藥業集團股份有限公司 )**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 9989)**

*English Version:*  
(Chinese Version)  
(Chinese Version)  
(Chinese Version)

*Chinese Version:*  
21  
21  
21

*English Version:*  
21  
21  
21

*Chinese Version:*  
4724, 471  
30  
30

*Chinese Version:*  
20, 2023

**2022 WORK REPORT OF THE BOARD OF DIRECTORS  
2022 WORK REPORT OF THE SUPERVISORY COMMITTEE  
2022 ANNUAL REPORT AND ITS SUMMARY,  
H SHARES RESULTS ANNOUNCEMENT,  
H SHARES 2022 ANNUAL REPORT,  
2022 CORPORATE GOVERNANCE REPORT AND  
2022 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT  
2022 FINAL FINANCIAL REPORT  
2022 PROFIT DISTRIBUTION PROPOSAL  
RE-APPOINTMENT OF AUDITORS OF THE COMPANY  
ELECTION OF THE SIXTH SESSION OF THE BOARD  
REMUNERATION OF INDEPENDENT NON-EXECUTIVE DIRECTORS OF  
THE SIXTH SESSION OF THE BOARD  
ELECTION OF THE SIXTH SESSION OF THE SUPERVISORY COMMITTEE  
PURCHASE OF WEALTH MANAGEMENT PRODUCTS AND  
CASH FLOW MANAGEMENT  
USING INTERNAL FUNDS  
APPLICATION FOR CREDIT LINE AND PROVIDING GUARANTEE TO  
CERTAIN BANKS FOR 2023  
AMENDMENT OF ARTICLES OF ASSOCIATION**

---

## LETTER FROM THE BOARD

---

### 1. INTRODUCTION

The Board of Directors (the "Board") of the Company has reviewed the 2022 Annual Report of the Company and the 2022 Annual General Meeting of the Company.

The Board has reviewed the 2022 Annual Report of the Company and the 2022 Annual General Meeting of the Company.

- (1) The Board has reviewed the 2022 Annual Report of the Company and the 2022 Annual General Meeting of the Company.
- (2) The Board has reviewed the 2022 Annual Report of the Company and the 2022 Annual General Meeting of the Company.
- (3) The Board has reviewed the 2022 Annual Report of the Company and the 2022 Annual General Meeting of the Company.
- (4) The Board has reviewed the 2022 Annual Report of the Company and the 2022 Annual General Meeting of the Company.
- (5) The Board has reviewed the 2022 Annual Report of the Company and the 2022 Annual General Meeting of the Company.
- (6) The Board has reviewed the 2022 Annual Report of the Company and the 2022 Annual General Meeting of the Company.
- (7) The Board has reviewed the 2022 Annual Report of the Company and the 2022 Annual General Meeting of the Company.
- (8) The Board has reviewed the 2022 Annual Report of the Company and the 2022 Annual General Meeting of the Company.
- (9) The Board has reviewed the 2022 Annual Report of the Company and the 2022 Annual General Meeting of the Company.

The Board has reviewed the 2022 Annual Report of the Company and the 2022 Annual General Meeting of the Company.

- (10) The Board has reviewed the 2022 Annual Report of the Company and the 2022 Annual General Meeting of the Company.
- (11) The Board has reviewed the 2022 Annual Report of the Company and the 2022 Annual General Meeting of the Company.
- (12) The Board has reviewed the 2022 Annual Report of the Company and the 2022 Annual General Meeting of the Company.

### 2. MATTERS TO BE CONSIDERED AT THE ANNUAL GENERAL MEETING

#### i. 2022 Work Report of the Board of Directors

The Board has reviewed the 2022 Annual Report of the Company and the 2022 Annual General Meeting of the Company.

The Board has reviewed the 2022 Annual Report of the Company and the 2022 Annual General Meeting of the Company.

The Board has reviewed the 2022 Annual Report of the Company and the 2022 Annual General Meeting of the Company.

---

## LETTER FROM THE BOARD

---

### ii. 2022 Work Report of the Supervisory Committee

The Board of Directors has reviewed the 2022 Work Report of the Supervisory Committee and the 2022 Annual Report of the Supervisory Committee, which were approved by the Board of Directors on December 29, 2023. The Board of Directors has also reviewed the 2022 Work Report of the Supervisory Committee and the 2022 Annual Report of the Supervisory Committee, which were approved by the Board of Directors on December 29, 2023.

### iii. 2022 Annual Report and its Summary, H Shares Results Announcement, H Shares 2022 Annual Report, 2022 Corporate Governance Report and 2022 Environmental, Social and Governance Report

The Board of Directors has reviewed the 2022 Annual Report and its Summary, H Shares Results Announcement, H Shares 2022 Annual Report, 2022 Corporate Governance Report and 2022 Environmental, Social and Governance Report, which were approved by the Board of Directors on December 29, 2023. The Board of Directors has also reviewed the 2022 Annual Report and its Summary, H Shares Results Announcement, H Shares 2022 Annual Report, 2022 Corporate Governance Report and 2022 Environmental, Social and Governance Report, which were approved by the Board of Directors on December 29, 2023.

### iv. 2022 Final Financial Report

The Board of Directors has reviewed the 2022 Final Financial Report, which was approved by the Board of Directors on December 29, 2023. The Board of Directors has also reviewed the 2022 Final Financial Report, which was approved by the Board of Directors on December 29, 2023.

### v. 2022 Profit Distribution Proposal

The Board of Directors has reviewed the 2022 Profit Distribution Proposal, which was approved by the Board of Directors on December 29, 2023. The Board of Directors has also reviewed the 2022 Profit Distribution Proposal, which was approved by the Board of Directors on December 29, 2023.

The Board of Directors has reviewed the 2022 Profit Distribution Proposal, which was approved by the Board of Directors on December 29, 2023. The Board of Directors has also reviewed the 2022 Profit Distribution Proposal, which was approved by the Board of Directors on December 29, 2023.

---

## LETTER FROM THE BOARD

---

### vi. Re-appointment of auditors of the Company

The Board of Directors of the Company, at its 139th meeting held on September 29, 2023, resolved to re-appoint the current auditors, PricewaterhouseCoopers ("PwC"), to audit the Company's financial statements for the year ending December 31, 2023.

The Board also resolved to authorize the Company's management to execute all necessary procedures to implement the above resolution.

### vii. Election of the sixth session of the Board

The Board of Directors of the Company, at its 139th meeting held on September 29, 2023, resolved to elect the following members to the sixth session of the Board: (Mr. Li), (Ms. Li), (Mr. Shan), (Dr. Lu), (Mr. Zhang), (Mr. Huang), and (Mr. Yi).



## LETTER FROM THE BOARD



[illegible]

3.4. A. 14.  $\frac{4}{4}$



A . . . A | . . . A | . . . A



| . . . A | . . . A | . . . A

**viii. Remuneration of independent non-executive Directors of the sixth session of the Board**

100,000 ( ),

A

**ix. Election of the sixth session of the Supervisory Committee**

Q. 184. A. A. A. ( Mr. Zheng ) ( Ms. Tang ) A.

---

## LETTER FROM THE BOARD

---

董事鄭澤輝先生(鄭澤輝), 53, 於2006年加入本公司, 2006年11月獲委任為本公司董事。鄭先生於1992年加入本公司, 2011年11月獲委任為本公司董事。

董事唐海均先生(唐海均), 44, 於2001年加入本公司, 2007年11月獲委任為本公司董事。唐先生於2014年11月獲委任為本公司董事。

董事A先生, 44, 於2001年加入本公司, 2007年11月獲委任為本公司董事。A先生於2014年11月獲委任為本公司董事。A先生於2001年加入本公司, 2007年11月獲委任為本公司董事。A先生於2014年11月獲委任為本公司董事。

董事B先生, 44, 於2001年加入本公司, 2007年11月獲委任為本公司董事。B先生於2014年11月獲委任為本公司董事。B先生於2001年加入本公司, 2007年11月獲委任為本公司董事。B先生於2014年11月獲委任為本公司董事。

董事C先生, 44, 於2001年加入本公司, 2007年11月獲委任為本公司董事。C先生於2014年11月獲委任為本公司董事。C先生於2001年加入本公司, 2007年11月獲委任為本公司董事。C先生於2014年11月獲委任為本公司董事。

董事D先生, 44, 於2001年加入本公司, 2007年11月獲委任為本公司董事。D先生於2014年11月獲委任為本公司董事。D先生於2001年加入本公司, 2007年11月獲委任為本公司董事。D先生於2014年11月獲委任為本公司董事。

董事E先生, 44, 於2001年加入本公司, 2007年11月獲委任為本公司董事。E先生於2014年11月獲委任為本公司董事。E先生於2001年加入本公司, 2007年11月獲委任為本公司董事。E先生於2014年11月獲委任為本公司董事。

---

## LETTER FROM THE BOARD

---

### x. Purchase of Wealth Management Products and Cash Flow Management Using Internal Funds

The Board has approved the purchase of wealth management products and cash flow management using internal funds for the year ending December 31, 2023.

The Board has also approved the purchase of wealth management products and cash flow management using internal funds for the year ending December 31, 2023.

### xi. Application for Credit Line and Providing Guarantee to Certain Banks for 2023

The Board has approved the application for credit line and providing guarantee to certain banks for the year ending December 31, 2023.

The Board has also approved the application for credit line and providing guarantee to certain banks for the year ending December 31, 2023.

### xii. Amendment of Articles of Association

The Board has approved the amendment of the Articles of Association for the year ending December 31, 2023.

The Board has also approved the amendment of the Articles of Association for the year ending December 31, 2023.

## 3. ANNUAL GENERAL MEETING AND CLOSURE OF REGISTER OF MEMBERS OF H SHARES

The Board has approved the annual general meeting and closure of register of members of H shares for the year ending December 31, 2023.

Figure 1. The effect of the concentration of the *Agrobacterium* suspension on the transformation efficiency of *Agrobacterium* strains A and E. The number of transformed cells was determined by the number of colonies obtained on the selective medium. The results are the mean of three independent experiments. Error bars represent the standard deviation. A, *Agrobacterium* strain A; E, *Agrobacterium* strain E.

2023, 29, 2023, 31, 2023, 17/ 25, 2023. 31, 2023 2022 A

A

☒ 10 ☒

## 5. RECOMMENDATION

[illegible]

Li Li

C. 2.

12

(李坦),  $I_{\text{max}} = 58$ ,  $\sigma = 0.67$ ,  $R^2 = 0.99$ ,  $n = 10$

28

A.

A, 1998; A, 2007; A, 2007; A, 2014; A, 2010; A, 2015; A, 2016.

1987 2005.

A ..... 922,391,179 A .....  
 73.96% ..... A ..... A ..... ( )  
 408,041,280 A ..... ( ..... 99.00% .....  
 1.00% .....  
 ); ( ) 474,029,899 A ..... ( .....  
 99.00% ..... 1.00% .....  
 ( ) 40,320,000 A ..... ( .....  
 ).

(iii) *Mr. Shan Yu*

(單宇), 62, 28, 1982, 2005. 1998. 2000; 2007; 2009; 2009; 2010; 2013; 2014.

1982 2005. 1998. 2000; 2007; 2009; 2009; 2010; 2013; 2014.

1982 2005.

A 99% 46,425,600 A 38.88% 15,118,035 A 52,302,892 A 3.56%

(iv) *Mr. Zhang Ping*

(張平), 58, 1992, 1998,

30, 2021, A, 2022, A, 2002, 2021, 1988, 2002.

A, A, A, A.



A. The  $^{13}\text{C}$  NMR spectrum of the polymer prepared from  $\text{CH}_3\text{COCH}_3$  and  $\text{CH}_3\text{COCH}_2\text{CH}_3$  in the presence of  $\text{CH}_3\text{COCH}_2\text{CH}_3$  is shown in Figure 1. The spectrum shows a broad peak at  $\delta = 13.51(2)$  ppm, which is assigned to the  $\text{CH}_3$  group of the polymer chain. The peak at  $\delta = 13.51(2)$  ppm is also observed in the spectrum of the polymer prepared from  $\text{CH}_3\text{COCH}_3$  and  $\text{CH}_3\text{COCH}_2\text{CH}_3$  in the presence of  $\text{CH}_3\text{COCH}_3$ .

(v) *Dr. Lu Chuan*

1991, A. . 1994, . 1997, A. . 2005, . A. . 2005  
2018, . II .  
. (A. . : 300052) A. . 2008.  
A. . 2012, . ( : 8128) . 2008 . 2009,  
. ( : 1733) . 2010 . 2016,  
. 2011 . 2014.

A. 董事會成員名單及個人資料

(vi) *Mr. Huang Peng*

黃鵬 (黃鵬), 74, 1949, 廣東省揭陽市人, 2003 年 1 月 1 日開始在 1995 年 1 月 1 日開始在 1985 年 1 月 1 日開始在 1988 年 1 月 1 日開始在 (新時代企業家研究院) 擔任 董事。A. 董事會成員名單及個人資料 ( : 601890), ( : 301180), ( : 300819) & ( : 603828).

A. 董事會成員名單及個人資料 A. 董事會成員名單及個人資料 A. 董事會成員名單及個人資料

A. 董事會成員名單及個人資料

(vii) *Mr. Yi Ming*

易銘 (易銘), 46, 1977, 廣東省揭陽市人, 2002 年 1 月 1 日開始在 2014 年 1 月 1 日開始在 ( ) A. 董事會成員名單及個人資料 (A. ) A. 董事會成員名單及個人資料 2003 年 1 月 1 日開始在 2012 年 1 月 1 日開始在 2013 年 1 月 1 日開始在 2018 年 1 月 1 日開始在 2018 年 1 月 1 日開始在

A. 董事會成員名單及個人資料 A. 董事會成員名單及個人資料 A. 董事會成員名單及個人資料

A. 董事會成員名單及個人資料

[illegible]

☒ 18 ☒

☒ 19 ☒

# OF THE 2022 ANNUAL GENERAL MEETING

NOTICE OF THE 2022 A  
NOTICE IS HEREBY GIVEN 2022  
Company  
22, 2023  
2022.02.20.3

## ORDINARY RESOLUTIONS

1. 2022  
2. 2022  
3. 2022 A  
4. 2022  
5. 2022

## SPECIAL RESOLUTIONS 深圳市海

6. 2023  
7. 2023

---

## NOTICE OF THE 2022 ANNUAL GENERAL MEETING

---

### ORDINARY RESOLUTION

8. *Resolved, that the Board of Directors be authorized to take any and all actions necessary to carry out the duties of the Board of Directors.*

### SPECIAL RESOLUTION

9. *Resolved, that the Board of Directors be authorized to take any and all actions necessary to carry out the duties of the Board of Directors.*

### ORDINARY RESOLUTIONS


10. *Resolved, that the Board of Directors be authorized to take any and all actions necessary to carry out the duties of the Board of Directors.*
11. *Resolved, that the Board of Directors be authorized to take any and all actions necessary to carry out the duties of the Board of Directors.*
- 11.01 *Resolved, that the Board of Directors be authorized to take any and all actions necessary to carry out the duties of the Board of Directors.*
- 11.02 *Resolved, that the Board of Directors be authorized to take any and all actions necessary to carry out the duties of the Board of Directors.*
- 11.03 *Resolved, that the Board of Directors be authorized to take any and all actions necessary to carry out the duties of the Board of Directors.*
- 11.04 *Resolved, that the Board of Directors be authorized to take any and all actions necessary to carry out the duties of the Board of Directors.*

---

## NOTICE OF THE 2022 ANNUAL GENERAL MEETING

---

12. 审议《关于向特定对象发行可转换公司债券募集资金运用的可行性分析报告》的议案；
- 12.01 审议《关于向特定对象发行可转换公司债券募集资金运用的可行性分析报告》的议案；
- 12.02 审议《关于向特定对象发行可转换公司债券募集资金运用的可行性分析报告》的议案；
- 12.03 审议《关于向特定对象发行可转换公司债券募集资金运用的可行性分析报告》的议案；
13. 审议《关于向特定对象发行可转换公司债券募集资金运用的可行性分析报告》的议案；
- 13.01 审议《关于向特定对象发行可转换公司债券募集资金运用的可行性分析报告》的议案；
- 13.02 审议《关于向特定对象发行可转换公司债券募集资金运用的可行性分析报告》的议案；

  
**Shenzhen Hepalink Pharmaceutical Group Co., Ltd.**  
**Li Li**  
C. 2023

2023年12月20日





---

## NOTICE OF THE 2022 ANNUAL GENERAL MEETING

---

(iii) The Board of Directors shall have the authority to determine the specific terms and conditions of the dividend, including the date of payment, the record date for determining eligibility to receive the dividend, and the method of payment (cash or stock). The Board of Directors may also determine the frequency of dividends, subject to the approval of the shareholders at the Annual General Meeting.

9. The Board of Directors shall have the authority to <sup>K</sup> determine the specific terms and conditions of the dividend, including the date of payment, the record date for determining eligibility to receive the dividend, and the method of payment (cash or stock).